8-K: Calidi Biotherapeutics Reports Q1 2025 Financial Results and Highlights Redtail Platform Progress

Calidi Biotherapeutics announced its Q1 2025 financial results, highlighting key operational advancements including the selection of an IL15-superagonist payload for its Redtail platform and FDA clearance for its CLD-201 clinical trial.

Summary

• Calidi Biotherapeutics reported a net loss attributable to common stockholders of $5.0 million, or $0.18 per share, for the first quarter ended March 31, 2025.
• This compares to a net loss of $7.2 million, or $2.03 per share, for the same period in 2024.
• Research and development expenses were $2.4 million, down from $2.7 million in Q1 2024.
• General and administrative expenses decreased to $2.6 million from $4.0 million in the prior year's quarter.
• The company's cash position increased to $10.6 million as of March 31, 2025, from $9.6 million at the end of 2024.
• The FDA cleared the IND application for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors.
• Calidi expects to file an IND for its Redtail platform with IL15-superagonist payload in the second half of 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reduced net loss, increased cash position, FDA clearance of CLD-201, and the appointment of experienced executives. However, the ongoing net loss and the risks associated with clinical trials temper the overall sentiment.

Positives

• The net loss decreased from $7.2 million in Q1 2024 to $5.0 million in Q1 2025.
• The company's cash position increased by approximately $1 million during the quarter.
• The FDA cleared the IND application for CLD-201.
• Calidi appointed a new CEO and Chief Medical Officer with extensive experience.
• Preclinical data on the Redtail platform was presented at the AACR Annual Meeting.

Negatives

• The company reported a net loss of $5.0 million for Q1 2025.
• The company is still loss making.

Risks

• The company may face challenges in raising sufficient capital to support its clinical trials.
• Early clinical trial results may not be indicative of final results.
• The company may not receive FDA approval for its therapeutic candidates.

Future Outlook

Calidi anticipates key milestones including reporting interim clinical results and dosing patients in planned clinical trials, while also focusing on the safety and efficacy of its therapeutic candidates.

Management Comments

• Eric Poma, PhD, CEO of Calidi Biotherapeutics, stated that the company is extremely excited about the progress at Calidi.
• Dr. Poma believes the Redtail platform will be a substantial breakthrough in the field of oncolytic viruses and tumor-targeted gene therapies.

Industry Context

Calidi is operating in the competitive immuno-oncology space, focusing on oncolytic viruses and targeted immunotherapies, similar to companies like Amgen (with its oncolytic virus Imlygic) and others developing gene therapies for cancer. The company's Redtail platform aims to improve systemic delivery and tumor targeting, addressing a key challenge in the field.

Comparison to Industry Standards

• Calidi's approach to systemic delivery of oncolytic viruses is similar in concept to companies like BioNTech, which are also exploring mRNA-based cancer therapies.
• The focus on IL-15 superagonists aligns with broader industry interest in harnessing the immune system to fight cancer, as seen with companies like Alkermes developing IL-15 based immunotherapies.
• The development of allogeneic stem cell-based immunotherapies like CLD-201 is comparable to efforts by companies like Fate Therapeutics, which are also working on off-the-shelf cell therapies for cancer.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the reduced net loss and progress in clinical development.
• Employees may benefit from the new leadership and advancement of key programs.
• Patients with solid tumors may have new treatment options in the future if CLD-201 and Redtail are successful.

Next Steps

• Advance CLD-201 into clinical development for the treatment of solid tumors.
• File an IND for the Redtail platform with IL15-superagonist payload in the second half of 2026.
• Continue preclinical and clinical development of other therapeutic candidates.

Key Dates

Keywords

Calidi Biotherapeutics, financial results, Redtail platform, CLD-201, IND, oncolytic virus, immunotherapy, biotechnology